
Please try another search
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Peter Gasser | - | - | Member of Scientific Advisory Board |
Kim PC Kuypers | - | - | Scientific Collaborator & Advisor |
Robert C. Malenka | - | 2021 | Chair of Scientific Advisory Board |
Carol A. Vallone | 68 | 2021 | Independent Chairperson |
Andreas R. Krebs | 67 | 2021 | Independent Vice Chairman |
Robert H. Dworkin | - | 2021 | Member of Scientific Advisory Board |
Robert Barrow | 36 | 2021 | CEO & Director |
Peter Bergethon | - | 2021 | Member of Scientific Advisory Board |
Suzanne L. Bruhn | 62 | 2022 | Independent Director |
Maurizio Fava | - | 2021 | Member of Scientific Advisory Board |
Roger Crystal | 49 | 2022 | Independent Director |
David W. Gryska | 70 | 2023 | Independent Director |
Maria A. Oquendo | - | 2021 | Member of Scientific Advisory Board |
Paul Summergrad | - | 2024 | Member of Scientific Advisory Board |
Nzinga Harrison | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review